

# Product Data Sheet

## Animal-Free BMP-13/GDF-6 Protein, Human (His)

Cat. No.:	HY-P700022AF
Synonyms:	subunit (CLMF p35); NK cell Stimulating Factor Chain 1
Species:	Human
Source:	E. coli
Accession:	Q6KF10 (T336-R455)
Gene ID:	392255
Molecular Weight:	Approximately 14.50 kDa

AA Sequence M T A F A S R H G K R H G K K S R L R C S K K P L H V N F K E L G W D D W I I A P L E Y E A Y H C E G V C D F P L R S H L E P T N H A I I Q T L M N S M D P G S T P P S C C V P T K L T P I S I L Y I D A G N N V V Y K Q Y E D M V V E S C G C R	PROPERTIES	
MTAFASRHGK       RHGKKSRLRC       SKKPLHVNFK       ELGWDDWIIA         PLEYEAYHCE       GVCDFPLRSH       LEPTNHAIIQ       TLMNSMDPGS         TPPSCCVPTK       LTPISILYID       AGNNVVYKQY       EDMVVESCGC         R       Measure by its ability to induce alkaline phosphatase production by ATDC5 cells. The ED <sub>50</sub> for this effect is 63-240 ng/         Appearance       Lyophilized powder.         Formulation       Lyophilized from a solution containing 20 mM sodium citrate, 0.2 MNaCl, pH 3.5.         Endotoxin Level       -0.1 EU per 1 µg of the protein by the LAL method.	PROPERTIES	
PLEYEAYHCE GVCDFPLRSH LEPTNHAIIQ TLMNSMDPGS   TPPSCCVPTK LTPISILYID AGNNVVYKQY EDMVVESCGC   R Measure by its ability to induce alkaline phosphatase production by ATDC5 cells. The ED50 for this effect is 63-240 ng/   Appearance Lyophilized powder.   Formulation Lyophilized from a solution containing 20 mM sodium citrate, 0.2 MNaCl, pH 3.5.   Endotoxin Level -1 EU per 1 µg of the protein by the LAL method.	AA Sequence	
TPPSCCVPTK       TTPISILYID       AGNNVVYKQY       EDMVVESCGC         Biological Activity       Measure by its ability to induce alkaline phosphatase production by ATDC5 cells. The ED50 for this effect is 63-240 ng/         Appearance       Lyophilized powder.         Formulation       Lyophilized from a solution containing 20 mM sodium citrate, 0.2 MNaCl, pH 3.5.         Endotoxin Level       -0.1 EU per 1 µg of the protein by the LAL method.		
R   Biological Activity   Measure by its ability to induce alkaline phosphatase production by ATDC5 cells. The ED <sub>50</sub> for this effect is 63-240 ng/   Appearance   ity ophilized powder.   Formulation   Lyophilized from a solution containing 20 mM sodium citrate, 0.2 MNaCl, pH 3.5.   Endotoxin Level		
Biological Activity       Measure by its ability to induce alkaline phosphatase production by ATDC5 cells. The ED <sub>50</sub> for this effect is 63-240 ng/         Appearance       Lyophilized powder.         Formulation       Lyophilized from a solution containing 20 mM sodium citrate, 0.2 MNaCl, pH 3.5.         Endotoxin Level       <0.1 EU per 1 µg of the protein by the LAL method.		
Appearance       Lyophilized powder.         Formulation       Lyophilized from a solution containing 20 mM sodium citrate, 0.2 MNaCl, pH 3.5.         Endotoxin Level       <0.1 EU per 1 µg of the protein by the LAL method.		
Appearance       Lyophilized powder.         Formulation       Lyophilized from a solution containing 20 mM sodium citrate, 0.2 MNaCl, pH 3.5.         Endotoxin Level       <0.1 EU per 1 µg of the protein by the LAL method.		
Appearance       Lyophilized powder.         Formulation       Lyophilized from a solution containing 20 mM sodium citrate, 0.2 MNaCl, pH 3.5.         Endotoxin Level       <0.1 EU per 1 µg of the protein by the LAL method.		
Formulation       Lyophilized from a solution containing 20 mM sodium citrate, 0.2 MNaCl, pH 3.5.         Endotoxin Level       <0.1 EU per 1 µg of the protein by the LAL method.	Biological Activity	
Formulation       Lyophilized from a solution containing 20 mM sodium citrate, 0.2 MNaCl, pH 3.5.         Endotoxin Level       <0.1 EU per 1 µg of the protein by the LAL method.		
Endotoxin Level <0.1 EU per 1 µg of the protein by the LAL method.	Appearance	
Endotoxin Level <0.1 EU per 1 µg of the protein by the LAL method.		
	Formulation	
<b>Reconstitution</b> It is not recommended to reconstitute to a concentration less than $100 \text{ ug/m}$ in ddH <sub>2</sub> O	Endotoxin Level	
<b>Reconsitivition</b> It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH <sub>2</sub> O		
it is not reconstitute to a concentration tess than 100 µg/mE in duri20.	Reconsititution	
<b>Storage &amp; Stability</b> Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). I	Storage & Stability	
recommended to freeze aliquots at -20°C or -80°C for extended storage.		
Shipping Room temperature in continental US;may vary elsewhere.	Shipping	

#### DESCRIPTION

#### Background

Animal-Free BMP-13/GDF-6 Protein, a pivotal growth factor, governs crucial processes, including proliferation and cellular differentiation in the retina and bone formation. Its regulatory role in apoptosis during retinal development is essential, contributing to the establishment of dorsal-ventral positional information and controlling the formation of the retinotectal map. In the context of skeletal development, this growth factor is indispensable for the normal formation of bones and joints in diverse anatomical regions, such as limbs, skull, digits, and axial skeleton. Additionally, it plays a key role in delineating boundaries between skeletal elements, suggesting a role in species-specific skeletal evolution. Functionally, BMP-13/GDF-6 exhibits positive regulation of chondrogenic tissue differentiation through specific growth factor receptor

subunits, including BMPR1A, BMPR1B, BMPR2, and ACVR2A, culminating in the activation of the SMAD1-SMAD5-SMAD8 complex. Notably, NOG serves as an inhibitor in the regulation of chondrogenic differentiation. Furthermore, BMP-13/GDF-6 is implicated in the induction of adipogenesis from mesenchymal stem cells, engaging growth factor receptors BMPR1A, BMPR2, and ACVR2A, and activating the SMAD1-SMAD5-SMAD8 complex and MAPK14/p38 through a mechanism of homodimerization with disulfide-linked structures.

### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA